American Society of Hirudotherapy

Pharmacology

From leech biology to three FDA-approved pharmaceuticals

Last Updated: May 27, 2026ASH Editorial · based on the books
9 FDA-approved drugs profiled — 3 derived from leech hirudin: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.191+ preclinical compounds: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.

Drug-vs-leech distinction

FDA-approved drug: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.

Bivalirudin, lepirudin, desirudin (hirudin-derived) and dabigatran (synthetic)

Approval:
FDA-approved drugs (NDA/BLA pathways)
Indication:
PCI anticoagulation, atrial fibrillation, HIT, VTE
Derived from:
Hirudin from Hirudo medicinalis (bivalirudin, lepirudin, desirudin); dabigatran is synthetic and not leech-derived
FDA-cleared medical device: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.

Hirudo medicinalis / Hirudo verbana

FDA status:
FDA-cleared medical device (H. medicinalis: K040187, 2004; H. verbana: K132958, 2014)
Cleared indication:
Venous congestion in surgical flaps and replanted tissue

These are two distinct regulatory contexts. The drug above is a recombinant or synthetic pharmaceutical analog regulated under FDA NDA/BLA pathways. The whole-leech therapy is regulated as a medical device. Clinical claims for the drug do NOT extend to whole-leech therapy, and vice versa.

200 compounds catalogued in ASH Compound Reference

Each compound page distinguishes whole-leech therapy from purified / recombinant / synthetic-analog pharmaceutical derivatives, with explicit clinical-translation-limit statements preventing mechanism-to-claim leakage.

Medicinal leech biology has directly inspired three FDA-approved direct thrombin inhibitors and the injectable direct thrombin inhibitors hirudin and bivalirudin originated from the observation that leech salivary extracts prevent blood clotting (Coppens et al., Circ Res, 2012; PMID: 22982873) (bivalirudin is widely used in primary PCI; Stone et al., N Engl J Med, 2008; PMID: 18499566). The leech accounts for two approved venom-derived drugs (bivalirudin and desirudin).

Important Distinction

FDA-approved drugs derived from leech hirudin (bivalirudin, desirudin, lepirudin) — plus dabigatran, a synthetic inhibitor designed from NAPAP rather than from hirudin — are separate pharmaceutical products, not leech therapy. These pages document the translational pipeline from zoopharmaceutical biology to clinical medicine.

The Translational Pipeline

Leech SGS→Native Hirudin→Recombinant Hirudin→Bivalirudin (FDA 2000)→Dabigatran (FDA 2010)

Topics

By the Numbers

3

FDA-Approved DTIs

$636M

Peak Bivalirudin Revenue

189

Salivary proteins identified in H. medicinalis

99%+

Unexploited as Drug Leads

Related Resources

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.